Hemophilia A

New England CEPAC
March 29, 2018 10am-4pm EST

Boston, MA

The New England CEPAC will convene to review the comparative clinical effectiveness and value of emicizumab for treatment of hemophilia A.

Key Dates

Associated Materials

08/11/2017

08/11/2017 – 09/06/2017

09/11/2017
Draft Scoping Document

09/11/2017 – 09/29/2017
Public Comments

10/10/2017
Revised Scoping Document

01/26/2018
Draft Voting Questions

01/26/2018
Draft Evidence Report

01/26/2018 – 02/23/2018
Public Comments

03/15/2018
Response to Comments

03/15/2018
Evidence Report

03/15/2018
Revised Voting Questions

03/29/2018
Meeting Agenda

03/29/2018
Evidence Presentation

04/12/2018
Final Evidence Report and Meeting Summary

04/12/2018
Report-at-a-Glance